Almirall launches Klisyri for actinic keratosis

Klisyri, a topical treatment for actinic keratosis, has been launched by Almirall following a December approval by the FDA, according to a press release.

Klisyri (tirbanibulin), a novel topical microtubule inhibitor, is indicated for AK treatment on the face and scalp.

In two phase 3 clinical studies, Klisyri achieved significantly higher rates of complete AK clearance compared with vehicle and met its secondary endpoint of partial skin clearance compared with vehicle.

“The incidence of actinic keratosis has been increasing, including in younger adults,” Ayman Grada, MD, head of R&D and medical affairs at Almirall U.S., said in the release. “Patients may prefer a treatment option with a short duration and proven safety and tolerability profile. The data for Klisyri offers this, as well as demonstrating efficacy for both face and scalp actinic keratoses.”